Pieris (PIRS) ground up steadily today, now 17%, apparently upon presentation of "IND-enabling" data at AACR (via freely released abstract):
PRS-343 at AACR
I own a bit, and it's in my charity portfolio, too. Their Hepcidin program may be obviated if FGEN succeeds, but other programs, like this one, look interesting. No recommendation here; it's a long term hold for me. It might pull back some, as it's had a good run lately, and this reaction to incremental data seems a little much, but I'd be wary of shorting, as there are other potential catalysts.
Cheers, Tuck. |
